The Future of Synthetic Carbohydrate Vaccines: Immunological Studies on Streptococcus pneumoniae Type 14 629
[21] Bentley SD, Aanensen DM, Mavroidi A, Saunders D, Rabbinowitsch E, Collins M,
Donohoe K, Harris D, Murphy L, Quail MA, Samuel G, Skovsted IC, Kaltoft MS, Barrell
B, Reeves PR, Parkhill J, Spratt BG. Genetic analysis of the capsular biosynthetic locus
from all 90 pneumococcal serotypes. PLoS.Genet. 2006;2(3):e31
[22] Mavroidi A, Aanensen DM, Godoy D, Skovsted IC, Kaltoft MS, Reeves PR, Bentley SD,
Spratt BG. Genetic relatedness of the Streptococcus pneumoniae capsular biosynthetic loci.
J.Bacteriol. 2007;189(21):7841-55.
[23] Llull D, Garcia E, Lopez R. Tts, a processive beta-glucosyltransferase of Streptococcus
pneumoniae, directs the synthesis of the branched type 37 capsular polysaccharide in
Pneumococcus and other gram-positive species. J Biol.Chem 2001;276(24):21053-61.
[24] Arrecubieta C, Lopez R, Garcia E. Type 3-specific synthase of Streptococcus pneumoniae
(Cap3B) directs type 3 polysaccharide biosynthesis in Escherichia coli and in
pneumococcal strains of different serotypes. J Exp.Med 1996;184(2):449-55.
[25] Breukels MA, Rijkers GT, Voorhorst-Ogink MM, Zegers BJ, Sanders LA. Pneumococcal
conjugate vaccine primes for polysaccharide-inducible IgG2 antibody response in
children with recurrent otitis media acuta. J.Infect.Dis. 1999;179(5):1152-6.
[26] Rennels MB, Edwards KM, Keyserling HL, Reisinger KS, Hogerman DA, Madore DV,
Chang I, Paradiso PR, Malinoski FJ, Kimura A. Safety and immunogenicity of
heptavalent pneumococcal vaccine conjugated to CRM
197
in United States infants.
Pediatrics 1998;101(4 Pt 1):604-11.
[27] Prymula R, Kriz P, Kaliskova E, Pascal T, Poolman J, Schuerman L. Effect of vaccination
with pneumococcal capsular polysaccharides conjugated to Haemophilus influenzae-
derived protein D on nasopharyngeal carriage of Streptococcus pneumoniae and H.
influenzae in children under 2 years of age. Vaccine 2009;28(1):71-8.
[28] French N. Use of pneumococcal polysaccharide vaccines: no simple answers. J.Infect.
2003;46(2):78-86.
[29] Ada G, Isaacs D. Carbohydrate-protein conjugate vaccines. Clin.Microbiol.Infect.
2003;9(2):79-85.
[30] Kalka-Moll WM, Tzianabos AO, Bryant PW, Niemeyer M, Ploegh HL, Kasper DL.
Zwitterionic polysaccharides stimulate T cells by MHC class II-dependent interactions. J
Immunol. 2002;169(11):6149-53.
[31] Choi YH, Roehrl MH, Kasper DL, Wang JY. A unique structural pattern shared by T-
cell-activating and abscess-regulating zwitterionic polysaccharides. Biochemistry
2002;41(51):15144-51.
[32] Karnezis TT, Smith A, Whittier S, Haddad J, Saiman L. Antimicrobial resistance among
isolates causing invasive pneumococcal disease before and after licensure of
heptavalent conjugate pneumococcal vaccine. PLoS One. 2009;4(6):e5965
[33] Valenzuela MT, de Quadros C. Antibiotic resistance in Latin America: a cause for alarm.
Vaccine 2009;27 Suppl 3:C25-C28
[34] Vlieghe E, Phoba MF, Tamfun JJ, Jacobs J. Antibiotic resistance among bacterial
pathogens in Central Africa: a review of the published literature between 1955 and
2008. Int.J Antimicrob.Agents 2009;34(4):295-303.
The Complex World of Polysaccharides
630
[35] Siira L, Rantala M, Jalava J, Hakanen AJ, Huovinen P, Kaijalainen T, Lyytikainen O,
Virolainen A. Temporal trends of antimicrobial resistance and clonality of invasive
Streptococcus pneumoniae isolates in Finland, 2002 to 2006. Antimicrob.Agents
Chemother. 2009;53(5):2066-73.
[36] Vila-Corcoles A, Bejarano-Romero F, Salsench E, Ochoa-Gondar O, de DC, Gomez-
Bertomeu F, Raga-Luria X, Cliville-Guasch X, Arija V. Drug-resistance in Streptococcus
pneumoniae isolates among Spanish middle aged and older adults with community-
acquired pneumonia. BMC.Infect.Dis. 2009;9:36
[37] Imai S, Ito Y, Ishida T, Hirai T, Ito I, Maekawa K, Takakura S, Iinuma Y, Ichiyama S,
Mishima M. High prevalence of multidrug-resistant Pneumococcal molecular
epidemiology network clones among Streptococcus pneumoniae isolates from adult
patients with community-acquired pneumonia in Japan. Clin.Microbiol.Infect. 2009;
[38] Shibl AM. Distribution of serotypes and antibiotic resistance of invasive pneumococcal
disease isolates among children aged 5 years and under in Saudi Arabia (2000-2004).
Clin.Microbiol.Infect. 2008;14(9):876-9.
[39] Yang F, Xu XG, Yang MJ, Zhang YY, Klugman KP, McGee L. Antimicrobial
susceptibility and molecular epidemiology of Streptococcus pneumoniae isolated from
Shanghai, China. Int.J.Antimicrob.Agents 2008;32(5):386-91.
[40] Gottlieb T, Collignon PJ, Robson JM, Pearson JC, Bell JM. Prevalence of antimicrobial
resistances in Streptococcus pneumoniae in Australia, 2005: report from the Australian
Group on Antimicrobial Resistance. Commun.Dis.Intell. 2008;32(2):242-9.
[41] Barocchi MA, Censini S, Rappuoli R. Vaccines in the era of genomics: the pneumococcal
challenge. Vaccine 2007;25(16):2963-73.
[42] O'Brien KL, Hochman M, Goldblatt D. Combined schedules of pneumococcal conjugate
and polysaccharide vaccines: is hyporesponsiveness an issue? Lancet Infect.Dis.
2007;7(9):597-606.
[43] Singleton RJ, Hennessy TW, Bulkow LR, Hammitt LL, Zulz T, Hurlburt DA, Butler JC,
Rudolph K, Parkinson A. Invasive pneumococcal disease caused by nonvaccine
serotypes among alaska native children with high levels of 7-valent pneumococcal
conjugate vaccine coverage. JAMA 2007;297(16):1784-92.
[44] Douglas RM, Paton JC, Duncan SJ, Hansman DJ. Antibody response to pneumococcal
vaccination in children younger than five years of age. J Infect.Dis. 1983;148(1):131-7.
[45] Ortqvist A, Hedlund J, Burman LA, Elbel E, Hofer M, Leinonen M, Lindblad I, Sundelof
B, Kalin M. Randomised trial of 23-valent pneumococcal capsular polysaccharide
vaccine in prevention of pneumonia in middle-aged and elderly people. Swedish
Pneumococcal Vaccination Study Group. Lancet 1998;351(9100):399-403.
[46] Teshale EH, Hanson D, Flannery B, Phares C, Wolfe M, Schuchat A, Sullivan P.
Effectiveness of 23-valent polysaccharide pneumococcal vaccine on pneumonia in HIV-
infected adults in the United States, 1998--2003. Vaccine 2008;26(46):5830-4.
[47] Veras MA, Enanoria WT, Castilho EA, Reingold AL. Effectiveness of the polysaccharide
pneumococcal vaccine among HIV-infected persons in Brazil: a case control study.
BMC.Infect.Dis. 2007;7:119
The Future of Synthetic Carbohydrate Vaccines: Immunological Studies on Streptococcus pneumoniae Type 14 631
[48] Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, Reingold A,
Cieslak PR, Pilishvili T, Jackson D, Facklam RR, Jorgensen JH, Schuchat A. Decline in
invasive pneumococcal disease after the introduction of protein-polysaccharide
conjugate vaccine. N.Engl.J.Med. 2003;348(18):1737-46.
[49] Pavia M, Bianco A, Nobile CG, Marinelli P, Angelillo IF. Efficacy of pneumococcal
vaccination in children younger than 24 months: a meta-analysis. Pediatrics
2009;123(6):e1103-e1110
[50] Isaacman DJ, McIntosh ED, Reinert RR. Burden of invasive pneumococcal disease and
serotype distribution among Streptococcus pneumoniae isolates in young children in
Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for
future conjugate vaccines. Int.J.Infect.Dis. 2009;14(3):e197-209.
[51] Knuf M, Szenborn L, Moro M, Petit C, Bermal N, Bernard L, Dieussaert I, Schuerman L.
Immunogenicity of routinely used childhood vaccines when coadministered with the
10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate
vaccine (PHiD-CV). Pediatr.Infect.Dis.J. 2009;28(4 Suppl):S97-S108
[52] Bermal N, Szenborn L, Chrobot A, Alberto E, Lommel P, Gatchalian S, Dieussaert I,
Schuerman L. The 10-valent pneumococcal non-typeable Haemophilus influenzae
protein D conjugate vaccine (PHiD-CV) coadministered with DTPw-HBV/Hib and
poliovirus vaccines: assessment of immunogenicity. Pediatr.Infect.Dis.J. 2009;28(4
Suppl):S89-S96
[53] Meng C, Lin H, Huang J, Wang H, Cai Q, Fang L, Guo Y. Development of 5-valent
conjugate pneumococcal protein A - Capsular polysaccharide pneumococcal vaccine
against invasive pneumococcal disease. Microb.Pathog. 2009;47(3):151-6.
[54] Bogaert D, de Groot R, Hermans PWM. Streptococcus pneumoniae colonisation: the key to
pneumococcal disease . Lancet.Infect.Dis. 2004;4:144-54.
[55] Xin W, Li Y, Mo H, Roland KL, Curtiss R, III. PspA family fusion proteins delivered by
attenuated Salmonella enterica serovar Typhimurium extend and enhance protection
against Streptococcus pneumoniae. Infect.Immun. 2009;77(10):4518-28.
[56] Francis JP, Richmond PC, Pomat WS, Michael A, Keno H, Phuanukoonnon S, Nelson JB,
Whinnen M, Heinrich T, Smith WA, Prescott SL, Holt PG, Siba PM, Lehmann D, van
den Biggelaar AH. Maternal antibodies to pneumolysin, but not pneumococcal surface
protein A, delay early pneumococcal carriage in high-risk Papua New Guinean infants.
Clin.Vaccine Immunol. 2009;16(11):1633-8.
[57] Ljutic B, Ochs M, Messham B, Ming M, Dookie A, Harper K, Ausar SF. Formulation,
stability and immunogenicity of a trivalent pneumococcal protein vaccine formulated
with aluminum salt adjuvants. Vaccine 2012;Epub ahead of print
[58] Pozsgay V. Recent developments in synthetic oligosaccharide-based bacterial vaccines.
Curr.Top.Med Chem 2008;8(2):126-40.
[59] Jansen WT, Snippe H. Short-chain oligosaccharide protein conjugates as experimental
pneumococcal vaccines. Indian.J.Med.Res. 2004;119:7-12.
[60] Benaissa-Trouw B, Lefeber DJ, Kamerling JP, Vliegenthart JF, Kraaijeveld K, Snippe H.
Synthetic polysaccharide type 3-related di-, tri-, and tetrasaccharide- CRM
197
conjugates
The Complex World of Polysaccharides
632
induce protection against Streptococcus pneumoniae type 3 in mice. Infect.Immun.
2001;69(7):4698-701.
[61] Plante OJ, Palmacci ER, Seeberger PH. Automated solid-phase synthesis of
oligosaccharides. Science 2001;291(5508):1523-7.
[62] Saksena R, Ma X, Wade TK, Kovác P, Wade WF. Length of the linker and the interval
between immunizations influences the efficacy of Vibrio cholerae O1,Ogawa
hexasaccharide neoglycoconjugates. FEMS Immunol.Med.Microbiol. 2006;47:116-28.
[63] Saksena R, Ma X, Wade TK, Kovac P, Wade WF. Effect of saccharide length on the
immunogenicity of neoglycoconjugates from synthetic fragments of the O-SP of Vibrio
cholerae O1, serotype Ogawa. Carbohydr.Res. 2005;340:2256-69.
[64] Bongat AF, Saksena R, Adamo R, Fujimoto Y, Shiokawa Z, Peterson DC, Fukase K,
Vann WF, Kovac P. Multimeric bivalent immunogens from recombinant tetanus toxin
H(C) fragment, synthetic hexasaccharides, and a glycopeptide adjuvant. Glycoconj.J.
2009;27(1):69-77.
[65] Phalipon A, Tanguy M, Grandjean C, Guerreiro C, Belot F, Cohen D, Sansonetti PJ,
Mulard LA. A synthetic carbohydrate-protein conjugate vaccine candidate against
Shigella flexneri 2a infection. J.Immunol. 2009;182(4):2241-7.
[66] Said HF, Phalipon A, Tanguy M, Guerreiro C, Belot F, Frisch B, Mulard LA, Schuber F.
Rational design and immunogenicity of liposome-based diepitope constructs:
application to synthetic oligosaccharides mimicking the Shigella flexneri 2a O-antigen.
Vaccine 2009;27(39):5419-26.
[67] Schofield L, Hewitt MC, Evans K, Siomos MA, Seeberger PH. Synthetic GPI as a
candidate anti-toxic vaccine in a model of malaria. Nature 2002;418(6899):785-9.
[68] Jeon I, Lee D, Krauss IJ, Danishefsky SJ. A new model for the presentation of tumor-
associated antigens and the quest for an anticancer vaccine: a solution to the synthesis
challenge via ring-closing metathesis. J.Am.Chem.Soc. 2009;131(40):14337-44.
[69] de Velasco EA, Verheul AF, Veeneman GH, Gomes LJ, van Boom JH, Verhoef J, Snippe
H. Protein-conjugated synthetic di- and trisaccharides of pneumococcal type 17F exhibit
a different immunogenicity and antigenicity than tetrasaccharide. Vaccine
1993;11(14):1429-36.
[70] Jansen WT, Verheul AFM, Veeneman GH, van Boom JH, Snippe H. Revised
interpretation of the immunological results obtained with pneumococcal
polysaccharide 17F derived synthetic di-, tri- and tetrasaccharide conjugates in mice
and rabbits. Vaccine 2002;20:19-21.
[71] de Velasco EA, Verheul AF, van Steijn AM, Dekker HA, Feldman RG, Fernandez IM,
Kamerling JP, Vliegenthart JF, Verhoef J, Snippe H. Epitope specificity of rabbit
immunoglobulin G (IgG) elicited by pneumococcal type 23F synthetic oligosaccharide-
and native polysaccharide-protein conjugate vaccines: comparison with human anti-
polysaccharide 23F IgG. Infect.Immun. 1994;62(3):799-808.
[72] Jansen WT, Hogenboom S, Thijssen MJL, Kamerling JP, Vliegenthart JFG, Verhoef J,
Snippe H, Verheul AFM. Synthetic 6B di-, tri-, and tetrasaccharide-protein conjugates
contain pneumococcal type 6A and 6B common and 6B-specific epitopes that elicit
protective antibodies in mice. Infect.Immun. 2001;69(2):787-93.
The Future of Synthetic Carbohydrate Vaccines: Immunological Studies on Streptococcus pneumoniae Type 14 633
[73] Safari D, Dekker HA, Joosten JA, Michalik D, de Souza AC, Adamo R, Lahmann M,
Sundgren A, Oscarson S, Kamerling JP, Snippe H. Identification of the smallest
structure capable of evoking opsonophagocytic antibodies against Streptococcus
pneumoniae type 14. Infect.Immun. 2008;76(10):4615-23.
[74] Mawas F, Niggemann J, Jones C, Corbel MJ, Kamerling JP, Vliegenthart JFG.
Immunogenicity in a mouse model of a conjugate vaccine made with a synthetic single
repeating unit of type 14 pneumococcal polysaccharide coupled to CRM
197
.
Infect.Immun. 2002;70(9):5107-14.
[75] Lindberg B, Lonngren J, Powel DA. Structural studies on the specific type 14
pneumococcal polysaccharide. Carbohydr.Res. 1977;58:177-86.
[76] Joosten JA, Lazet BJ, Kamerling JP, Vliegenthart JF. Chemo-enzymatic synthesis of tetra-
, penta-, and hexasaccharide fragments of the capsular polysaccharide of Streptococcus
pneumoniae type 14. Carbohydr.Res 2003;338(23):2629-51.
[77] Joosten JA, Kamerling JP, Vliegenthart JF. Chemo-enzymatic synthesis of a tetra- and
octasaccharide fragment of the capsular polysaccharide of Streptococcus pneumoniae type
14. Carbohydr.Res 2003;338(23):2611-27.
[78]
Michalik D, Vliegenthart JFG, Kamerling JP. Chemoenzymic synthesis of
oligosaccharide fragments of the capsular polysaccharide of Streptococcus pneumoniae
type 14. J.Chem.Soc., Perkin Trans.1 2002;1973-81.
[79] Sundgren A, Lahmann M, Oscarson S. Block synthesis of Streptococcus pneumoniae type
14 capsular polysaccharide structures. J.Carbohydr.Chem. 2005;24(4):379-91.
[80] Safari D, Dekker HA, Rijkers G, van der Ende A, Kamerling JP, Snippe H. The immune
response to group B streptococcus type III capsular polysaccharide is directed to the -
Glc-GlcNAc-Gal- backbone epitope. Glycoconj.J. 2011;28:557-67.
[81] Guttormsen HK, Baker CJ, Nahm MH, Paoletti LC, Zughaier SM, Edwards MS, Kasper
DL. Type III group B streptococcal polysaccharide induces antibodies that cross-react
with Streptococcus pneumoniae type 14. Infect.Immun. 2002;70(4):1724-38.
[82] Kadirvelraj R, Gonzalez-Quteirino J, Foley BL, Beckham ML, Jennings HJ, Foote S, Ford
MG, Woods RJ. Understanding the bacterial polysaccharide antigenicity of Streptococcus
agalactiae versus Streptococcus pneumoniae. Proc.Natl.Acad.Sci.USA 2007;103(21):8149-54.
[83] Jennings HJ, Lugowski C, Kasper DL. Conformational aspects critical to the
immunospecificity of the type III group B streptococcal polysaccharide. Biochemistry
1981;20(16):4511-8.
[84] Miernyk KM, Butler JC, Bulkow LR, Singleton RJ, Hennessy TW, Dentinger CM, Peters
HV, Knutsen B, Hickel J, Parkinson AJ. Immunogenicity and reactogenicity of
pneumococcal polysaccharide and conjugate vaccines in alaska native adults 55-70
years of age. Clin.Infect.Dis. 2009;49(2):241-8.
[85] Safari D, Dekker HA, de Jong B, Rijkers G, Kamerling JP, Snippe H. Antibody- and cell-
mediated immune responses to a synthetic oligosaccharide conjugate vaccine after
booster immunization. Vaccine 2011;29(38):6498-504.
[86] Lefeber DJ, Benaissa-Trouw B, Vliegenthart JFG, Kamerling JP, Jansen WTM,
Kraaijeveld K, Snippe H. Th1-directing adjuvants increase the immunogenicity of
The Complex World of Polysaccharides
634
oligosaccharide-protein conjugate vaccines related to Streptococcus pneumoniae type 3.
Infect.Immun. 2003;71(12):6915-20.
[87] Safari D, Dekker HA, Rijkers G, Snippe H. Codelivery of adjuvants at the primary
immunization site is essential for evoking a robust immune response to
neoglycoconjugates. Vaccine 2011;29(4):849-54.
Document Outline - Preface The Complex World of Polysaccharides
- Section 1 Sources and Biological Properties of Polysaccharides
- 01 Is Chitosan a New Panacea? Areas of Application
- 02 Yeast (Saccharomyces cerevisiae) Glucan Polysaccharides – Occurrence, Separation and Application
- 03 Mechanisms of O-Antigen Structural Variation of Bacterial Lipopolysaccharide (LPS)
- 04 Exopolysaccharide Biosynthesis in Rhizobium leguminosarum: From Genes to Functions
- 05 Capsular Polysaccharides Produced by the Bacterial Pathogen Burkholderia pseudomallei
- 06 Polysaccharides from Larch Biomass
- 07 Antiviral Levans from Bacillus spp. Isolated from Honey
- 08 Lichen Polysaccharides
- Section 2 Physical and Chemical Characteristics of Polysaccharides
- 09 The Molecular Structure and Conformational Dynamics of Chitosan Polymers: An Integrated Perspect
- 10 Concept of Template Synthesis of Proteoglycans
- 11 Coupled Mass Spectrometric Strategies for the Determination of Carbohydrates at Very Low Concent
- 12 Diatom Polysaccharides: Extracellular Production, Isolation and Molecular Characterization
- 13 Exopolysaccharides of the Biofilm Matrix: A Complex Biophysical World
- Section 3 Applications in the Food Industry
- 14 Polysaccharide-Protein Interactions and Their Relevance in Food Colloids
- 15 Chitosan: A Bioactive Polysaccharide in Marine-Based Foods
- 16 Polysaccharides as Carriers and Protectors of Additives and Bioactive Compounds in Foods
- 17 Dietary Fiber and Availability of Nutrients: A Case Study on Yoghurt as a Food Model
- 18 Plant Biotechnology for the Development of Design Starches
- Section 4 Applications in the Pharmaceutical Industry
- 19 Bioactive Polysaccharides of American Ginseng Panax quinquefolius L. in Modulation of Immune Fun
- 20 Polysaccharides from Red Algae: Genesis of a Renaissance
- 21 1,3--Glucans: Drug Delivery and Pharmacology
- 22 Complexes of Polysaccharides and Glycyrrhizic Acid with Drug Molecules − Mechanochemical Synthes
- 23 The Chitosan as Dietary Fiber: An in vitro Comparative Study of Interactions with Drug and Nutri
- 24 The Future of Synthetic Carbohydrate Vaccines: Immunological Studies on Streptococcus pneumoniae
Dostları ilə paylaş: |